Artikel ; Online: Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.
2023 Band 129, Heft 1, Seite(n) 122–134
Abstract: Background: HER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We aimed to estimate them between primary and recurrent tumours, and identify predictive factors.: ... ...
Abstract | Background: HER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We aimed to estimate them between primary and recurrent tumours, and identify predictive factors. Methods: We compared the HER2 status, and clinical and pathological characteristics by its evolution category (stable or changed), between all primary BCs and matched recurrences registered in our database in 2000-2020 (n = 512). Results: HER2-low tumours were the most prevalent at diagnosis (44.9%), followed by HER2-negative tumours (39.3%). HER2 status significantly changed in 37.3% of recurrences, mainly of HER2-negative and HER2-low tumours. HER2-negative tumours which relapsed as HER2-low significantly more frequently expressed oestrogen receptors (ER) and recurred later than stably HER2-negative tumours. Changed HER2 status in distant metastases correlated with lower proliferation rates and higher ER expression in primary tumours, and among metastases of hormone receptor-positive (HR+) tumours-with weak progesterone receptor (PR) expression in primary tumours. Conclusions: HER2 status changes with BC progression, with enrichment of HER2-low tumours in advanced stages. The ER+/PR- status, low proliferation index and time to late recurrence correlated with these changes. These findings highlight the need of retesting recurrences, especially of HR + primary tumours, to identify candidates for new anti-HER2 therapies. |
---|---|
Mesh-Begriff(e) | Humans ; Female ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Breast Neoplasms/genetics ; Breast Neoplasms/therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Disease Progression ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism |
Chemische Substanzen | Receptor, ErbB-2 (EC 2.7.10.1) ; Receptors, Estrogen ; Receptors, Progesterone ; Biomarkers, Tumor |
Sprache | Englisch |
Erscheinungsdatum | 2023-04-29 |
Erscheinungsland | England |
Dokumenttyp | Journal Article |
ZDB-ID | 80075-2 |
ISSN | 1532-1827 ; 0007-0920 |
ISSN (online) | 1532-1827 |
ISSN | 0007-0920 |
DOI | 10.1038/s41416-023-02287-x |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Uh III Zs.142: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.